Skip to content
drillr.ai
Sign up

688526.SH

科前生物

SSE · Healthcare · Biotechnology · CN

CNY 12.97
−0.92%
Ask drillr

  • Aug 26, 2026, 11:40 UTC

    Keqian Biology announced its first-half 2026 results: net profit attributable to shareholders was 116 million yuan, down 47.37% year-on-year.

    Source:

  • Aug 24, 2026, 10:15 UTC

    Keqian Biology received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its avian adenovirus (group I, type 4) inactivated vaccine (HB-2 strain) to be registered as a new veterinary drug, and obtained the new veterinary drug registration certificate.